X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with TIMKEN INDIA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs TIMKEN INDIA - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

TIMKEN INDIA 
   Change

Tata Timken Ltd. (TTL), the country`s second largest ball-bearing (tapered and cartridge tapered) manufacturer after SKF, has become an 80% subsidiary of the $2.4 billion family controlled Timken USA, after buying out the Tata`s 40% stake in the comp... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES TIMKEN INDIA INDOCO REMEDIES/
TIMKEN INDIA
 
P/E (TTM) x 47.1 55.0 85.6% View Chart
P/BV x 2.8 8.2 34.1% View Chart
Dividend Yield % 0.8 0.1 604.0%  

Financials

 INDOCO REMEDIES   TIMKEN INDIA
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
TIMKEN INDIA
Mar-17
INDOCO REMEDIES/
TIMKEN INDIA
5-Yr Chart
Click to enlarge
High Rs360675 53.4%   
Low Rs249435 57.3%   
Sales per share (Unadj.) Rs119.0155.3 76.6%  
Earnings per share (Unadj.) Rs8.414.3 58.5%  
Cash flow per share (Unadj.) Rs15.218.5 82.1%  
Dividends per share (Unadj.) Rs1.601.00 160.0%  
Dividend yield (eoy) %0.50.2 291.4%  
Book value per share (Unadj.) Rs70.790.9 77.8%  
Shares outstanding (eoy) m92.1568.00 135.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.63.6 71.7%   
Avg P/E ratio x36.438.8 93.8%  
P/CF ratio (eoy) x20.029.9 66.8%  
Price / Book Value ratio x4.36.1 70.6%  
Dividend payout %19.17.0 273.5%   
Avg Mkt Cap Rs m28,08337,743 74.4%   
No. of employees `0006.00.7 841.8%   
Total wages/salary Rs m2,167737 293.9%   
Avg. sales/employee Rs Th1,817.014,730.5 12.3%   
Avg. wages/employee Rs Th359.01,028.2 34.9%   
Avg. net profit/employee Rs Th127.71,355.6 9.4%   
INCOME DATA
Net Sales Rs m10,96810,562 103.8%  
Other income Rs m4099 40.0%   
Total revenues Rs m11,00710,661 103.2%   
Gross profit Rs m1,5651,580 99.0%  
Depreciation Rs m633289 219.0%   
Interest Rs m628 739.3%   
Profit before tax Rs m9091,382 65.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m139410 33.8%   
Profit after tax Rs m771972 79.3%  
Gross profit margin %14.315.0 95.4%  
Effective tax rate %15.329.7 51.4%   
Net profit margin %7.09.2 76.4%  
BALANCE SHEET DATA
Current assets Rs m5,7255,494 104.2%   
Current liabilities Rs m5,4542,331 234.0%   
Net working cap to sales %2.529.9 8.2%  
Current ratio x1.02.4 44.5%  
Inventory Days Days6265 95.7%  
Debtors Days Days7266 108.1%  
Net fixed assets Rs m5,3072,887 183.8%   
Share capital Rs m184680 27.1%   
"Free" reserves Rs m6,3315,499 115.1%   
Net worth Rs m6,5166,179 105.5%   
Long term debt Rs m1,3230-   
Total assets Rs m11,9708,727 137.2%  
Interest coverage x15.6165.5 9.5%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.91.2 75.7%   
Return on assets %7.011.2 61.9%  
Return on equity %11.815.7 75.2%  
Return on capital %12.422.5 55.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,5073,293 136.9%   
Fx outflow Rs m1,1412,491 45.8%   
Net fx Rs m3,366802 419.6%   
CASH FLOW
From Operations Rs m8861,642 54.0%  
From Investments Rs m-1,706-1,251 136.3%  
From Financial Activity Rs m1,316-47 -2,793.4%  
Net Cashflow Rs m497344 144.4%  

Share Holding

Indian Promoters % 59.2 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 12.5 5.5 227.3%  
FIIs % 6.0 6.4 93.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 13.2 169.7%  
Shareholders   12,805 49,890 25.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   GREENPLY IND  STC INDIA  FINOLEX IND.  COMMEX TECHNOLOGY  INGERSOLL RAND  



Today's Market

Sensex Opens 99 Points Down; Vedanta & Coal India Top Losers(09:30 am)

Asian share markets are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.9% while the Hang Seng is down 2%. The Shanghai Composite is trading down by 2.7%.

Related Views on News

TIMKEN INDIA Announces Quarterly Results (4QFY18); Net Profit Down 7.8%

May 25, 2018 | Updated on May 25, 2018

For the quarter ended March 2018, TIMKEN INDIA has posted a net profit of Rs 237 m (down 7.8% YoY). Sales on the other hand came in at Rs 3 bn (up 25.2% YoY). Read on for a complete analysis of TIMKEN INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Jun 18, 2018 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 5-YR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS